Sarepta Therapeutics (SRPT) says adverse event report was erroneously submitted to FDA's FAERs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sarepta Therapeutics (SRPT) to Resume Trading at 3:45 pm
August 8, 2019 3:34 PM EDTSarepta Therapeutics (NASDAQ: SRPT) to Resume Trading at 3:45 pm
... MoreSarepta Therapeutics (SRPT) option implied volatility at 55, call put ratio 1.6 calls to 1 put into trading halt
August 8, 2019 2:23 PM EDTSarepta Therapeutics (NASDAQ: SRPT) 30 day call option implied volatility is at 55 compared to its 52-week range of 48 to 87 into trading halt.
... MoreSarepta Therapeutics (SRPT) Weakness Should Be Bought - Nomura/Instinet
August 8, 2019 2:02 PM EDTNomura/Instinet analyst Christopher Marai reiterated a Buy rating and $230.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) with shares halted at noon pending news of an SAE potentially related to SRP-9001, made public on the FDA FAERs database; the SAE was disclosed to be due to rhabdomyolysis.
Marai commented, "The FAERs database... More
FDA Adverse Event May Not Be 'Major Showstopper' for Sarepta Therapeutics (SRPT) Program - RBC
August 8, 2019 1:08 PM EDTRBC Capital analyst Brian Abrahams weighed in on Sarepta Therapeutics (NASDAQ: SRPT) after the FDA's adverse events database cited a case of rhabdomyolysis leading to hospitalization in a patient who had received their microdystrophin gene therapy.
The analyst notes several reasons it may not be a major showstopper for the program:
1) The event occurred back in early February, and the trial continued with rapid enrollment for months thereafter,... More
Sarepta Therapeutics (SRPT) Halted, News Pending
August 8, 2019 12:29 PM EDTSarepta Therapeutics (NASDAQ: SRPT) Halted, News Pending
Sarepta Therapeutics (SRPT) Resumes Trading
August 8, 2019 12:20 PM EDTSarepta Therapeutics (NASDAQ: SRPT) Resumes Trading
... MoreSarepta Therapeutics (SRPT) Halted on LUDP
August 8, 2019 12:15 PM EDTSarepta Therapeutics (NASDAQ: SRPT) Halted on LUDP
Sarepta (SRPT) SRP-9001 Safety Issue Appears in FDA's FAERS System - Bloomberg
August 8, 2019 12:10 PM EDTSarepta's (NASDAQ: SRPT) SRP-9001 Safety Issue Appears in FDA's FAERS System - Bloomberg
